Free Trial
→ What’s Elon building now? (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Glaukos Corporation stock logo
GKOS
Glaukos
$165.37
+2.5%		$172.97
$73.16
▼
$191.62
$9.51B0.69995,454 shs1.20 million shs
Globus Medical, Inc. stock logo
GMED
Globus Medical
$74.69
+1.9%		$79.12
$56.50
▼
$101.40
$9.85B0.961.69 million shs1.08 million shs
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$27.22
+0.9%		$28.48
$26.12
▼
$37.51
$11.32B0.531.28 million shs982,896 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$77.87
-1.4%		$86.01
$60.10
▼
$156.00
$2.73B1.94801,040 shs733,654 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Glaukos Corporation stock logo
GKOS
Glaukos
+2.82%+1.19%-7.98%+8.27%+88.88%
Globus Medical, Inc. stock logo
GMED
Globus Medical
+1.81%-1.24%+0.10%-4.46%+23.49%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
+1.00%+2.88%-2.00%-11.31%-24.26%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-1.43%-2.41%-9.87%+9.32%-34.04%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Glaukos Corporation stock logo
GKOS
Glaukos
$165.37
+2.5%		$172.97
$73.16
▼
$191.62
$9.51B0.69995,454 shs1.20 million shs
Globus Medical, Inc. stock logo
GMED
Globus Medical
$74.69
+1.9%		$79.12
$56.50
▼
$101.40
$9.85B0.961.69 million shs1.08 million shs
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$27.22
+0.9%		$28.48
$26.12
▼
$37.51
$11.32B0.531.28 million shs982,896 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$77.87
-1.4%		$86.01
$60.10
▼
$156.00
$2.73B1.94801,040 shs733,654 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Glaukos Corporation stock logo
GKOS
Glaukos
+2.82%+1.19%-7.98%+8.27%+88.88%
Globus Medical, Inc. stock logo
GMED
Globus Medical
+1.81%-1.24%+0.10%-4.46%+23.49%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
+1.00%+2.88%-2.00%-11.31%-24.26%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-1.43%-2.41%-9.87%+9.32%-34.04%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Glaukos Corporation stock logo
GKOS
Glaukos
2.80
Moderate Buy$180.549.17% Upside
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.88
Moderate Buy$99.4633.17% Upside
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
2.00
Hold$31.9117.25% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.38
Hold$121.0055.39% Upside

Current Analyst Ratings Breakdown

Latest TMDX, SNN, GMED, and GKOS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/7/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$120.00
10/1/2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$115.00 ➝ $85.00
9/24/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C+) ➝ Hold (C)
9/22/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$190.00 ➝ $210.00
9/18/2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/11/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$33.88
9/11/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/8/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
9/8/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral
9/8/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
9/4/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Glaukos Corporation stock logo
GKOS
Glaukos
$612.84M15.92N/AN/A$11.42 per share14.48
Globus Medical, Inc. stock logo
GMED
Globus Medical
$2.94B3.41$6.40 per share11.67$33.86 per share2.21
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$6.16B1.85$3.46 per share7.86$12.45 per share2.19
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$605.49M4.44$3.87 per share20.12$13.79 per share5.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Glaukos Corporation stock logo
GKOS
Glaukos
-$187.69M-$3.25N/A306.24N/A-30.68%-6.37%-4.78%10/28/2026 (Confirmed)
Globus Medical, Inc. stock logo
GMED
Globus Medical
$537.87M$3.9119.1013.861.1817.02%14.57%12.62%11/5/2026 (Estimated)
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$625MN/AN/A11.781.49N/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$190.29M$3.8920.0234.461.0922.69%15.88%5.95%11/4/2026 (Estimated)

Latest TMDX, SNN, GMED, and GKOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.20N/AN/AN/A$792.28 millionN/A
11/4/2026Q3 2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.2976N/AN/AN/A$177.54 millionN/A
10/28/2026Q3 2026
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.0959N/AN/AN/A$168.01 millionN/A
8/6/2026Q2 2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.10$1.34+$0.24$1.10$782.88 million$789.61 million
8/4/2026Q2 2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.4955$0.44-$0.0555$0.41$184.00 million$189.95 million
7/29/2026Q2 2026
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.2105-$0.14+$0.0705-$0.31$150.93 million$185.61 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.592.17%N/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A

Latest TMDX, SNN, GMED, and GKOS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/4/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.31202.36%10/2/202610/2/202611/6/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Glaukos Corporation stock logo
GKOS
Glaukos
0.10
5.04
4.46
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/A
4.62
2.93
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.62
2.14
1.11
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.62
6.62
6.07

Institutional Ownership

CompanyInstitutional Ownership
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
25.64%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
Glaukos Corporation stock logo
GKOS
Glaukos
5.90%
Globus Medical, Inc. stock logo
GMED
Globus Medical
18.38%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
1.00%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
1,09458.98 million55.50 millionOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
6,000134.26 million109.59 millionOptionable
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
16,988419.93 million415.73 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
89834.56 million32.18 millionOptionable

Recent News About These Companies

Barclays Initiates Coverage on TransMedics Group (NASDAQ:TMDX)
October 9 at 2:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31101578
Barclays initiates coverage of TransMedics Group at overweight
October 8 at 7:36 PM  |  msn.comhttps://www.msn.com/en-us/news/other/barclays-initiates-coverage-of-transmedics-group-at-overweight/ar-AA2dRirB
TransMedics Group consensus price target rises 10.91% to MX$1,984.96
October 8 at 7:36 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/transmedics-group-consensus-price-target-rises-10-91-to-mx-1-984-96/ar-AA2dQz9a
41,109 TransMedics Group, Inc. $TMDX Shares Sold by Zevenbergen Capital Investments LLC
October 8 at 7:35 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-41109-transmedics-group-inc-tmdx-shares-sold-by-zevenbergen-capital-investments-llc-2026-10-08/
TransMedics Group stock gets USD 120.00 target from Barclays
October 8 at 2:35 PM  |  ad-hoc-news.deA
TransMedics Group (NASDAQ:TMDX) Shares Climb 4.2% - Time to Buy?
October 7 at 2:20 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-transmedics-group-nasdaq-tmdx-shares-climb-42-time-to-buy-2026-10-07/
TransMedics Group (NASDAQ:TMDX) Now Covered by Analysts at Barclays
October 7 at 9:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-transmedics-group-nasdaq-tmdx-now-covered-by-analysts-at-barclays-2026-10-07/
TransMedics Group, Inc. $TMDX Shares Purchased by Congress Asset Management Co.
October 7 at 3:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-transmedics-group-inc-tmdx-shares-purchased-by-congress-asset-management-co-2026-10-07/
TransMedics Group, Inc. (NASDAQ:TMDX) Stock Rated "Hold" by Sell-Side Analysts
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085607
TransMedics Group, Inc. (NASDAQ:TMDX) Stock Has Average Price Target of $121.10 According to Brokerages
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-transmedics-group-inc-nasdaq-tmdx-stock-has-average-price-target-of-12110-according-to-brokerages-2026-10-05/
TransMedics Group (TMDX) Stock Looks Below Fair Value On Earnings
October 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/transmedics-group-tmdx-stock-looks-090752981.html
Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)
October 3, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TMDX/pressreleases/4943383/analysts-have-conflicting-sentiments-on-these-healthcare-companies-transmedics-group-tmdx-regeneron-regn-and-tarsus-pharmaceuticals-tars/
Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)
October 3, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TMDX/pressreleases/4943383/analysts-have-conflicting-sentiments-on-these-healthcare-companies-transmedics-group-tmdx-regeneron-regn-and-tarsus-pharmaceuticals-tars/
TransMedics Group (TMDX) Could Be 19% Undervalued If Its Growth Narrative Holds
October 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/transmedics-group-tmdx-could-19-060700455.html
TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?
September 29, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/09/29/transmedics-director-david-weill-purchases-usd109-000-of-stock-should-investors-buy-too/
TransMedics (TMDX)
September 28, 2026  |  es.investing.comhttps://es.investing.com/equities/transmedics-group-inc
TransMedics Offers An Attractive Entry Point, With Upside Potential Outweighing Risks
September 26, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4949948-transmedics-offers-an-attractive-entry-point-with-upside-potential-outweighing-risks
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
September 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-transmedics-group-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302890731.html
Investors Purchase Large Volume of TransMedics Group Put Options (NASDAQ:TMDX)
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-investors-purchase-large-volume-of-transmedics-group-put-options-nasdaq-tmdx-2026-09-25/
Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and TransMedics Group (TMDX)
September 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TMDX/pressreleases/4750087/analysts-offer-insights-on-healthcare-companies-dbv-technologies-sa-american-dbvt-and-transmedics-group-tmdx/
【TMDX】TransMedics Group
September 19, 2026  |  note.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Glaukos stock logo

Glaukos NYSE:GKOS

$165.37 +4.08 (+2.53%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$165.64 +0.27 (+0.17%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Globus Medical stock logo

Globus Medical NYSE:GMED

$74.69 +1.36 (+1.85%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$74.65 -0.04 (-0.05%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Smith & Nephew SNATS stock logo

Smith & Nephew SNATS NYSE:SNN

$27.22 +0.26 (+0.95%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$27.24 +0.02 (+0.07%)
As of 10/9/2026 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$77.87 -1.13 (-1.43%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$78.44 +0.57 (+0.73%)
As of 10/9/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas